Search
Ellagic acid
go.drugbank.com/drugs/DB08846InvestigationalEllagic acid is an investigational drug studied for treatment of Follicular Lymphoma (phase 2 trial), protection from brain injury of intrauterine growth restricted babies (phase 1 and 2 trial), improvement
Buspirone
go.drugbank.com/drugs/DB00490ApprovedInvestigationalBuspirone is a novel anxiolytic agent with a unique structure and a pharmacological profile. Belonging to the azaspirodecanedione drug class, buspirone is a serotonin 5-HT1A receptor agonist that is not chemically or pharmacologically re...
Oral Polio Vaccine
go.drugbank.com/drugs/DB15864InvestigationalThe polio vaccine can be either administered in the inactivated form or the oral form, although both series comprises 4 doses and is also interchangeable in administration form so long all as 4 doses are
HGS-TR2J
go.drugbank.com/drugs/DB05895ExperimentalHGS-TR2J is a novel agonistic human monoclonal antibody to TRAIL Receptor 2, in patients with advanced solid malignancies. It is developed by Human Genome Sciences, Inc and is under Phase I of clinical trial.
MRx-4DP0004
go.drugbank.com/drugs/DB15751InvestigationalMRx-4DP0004 is a lyophilised formulation of the Bifidobacterium breve strain of commensal bacteria. It is a live biotherapeutic derived from the microbiota of a healthy human infant.
Filanesib
go.drugbank.com/drugs/DB06040InvestigationalFilanesib is a potent Kinesin Spindle Protein (KSP) inhibitor that caused marked tumor regression in preclinical models of human solid tumors and human leukemias, often leading to durable responses.
Tunicamycin
go.drugbank.com/drugs/DB13172ExperimentalIt is used as an experimental tool to induce unfolded protein response. Tunicamycin is produced by Streptomyces clavuligerus and Streptomyces lysosuperficus bacteria along with several other species.
Recombinant SARS-CoV-2 Vaccine (Sf9 Cell)
go.drugbank.com/drugs/DB16443InvestigationalIt also provided protection in non-human primates to an in vivo challenge with SARS-CoV-2[A226853].
Pegvaliase
go.drugbank.com/drugs/DB12839ApprovedInvestigationalPAH deficiency and inability to break down an amino acid phenylalanine (Phe) leads to elevated blood phenylalanine concentrations and accumulation of neurotoxic Phe in the brain, causing chronic intellectual … Food and Drug Administration and European Medicines Agency approved pegvaliase-pqpz in May 2018 for the treatment of adult patients with phenylketonuria (PKU).
SC-236
go.drugbank.com/drugs/DB14059ExperimentalSC-236 is a potent, selective, orally active inhibitor of cyclooxygenase-2 (COX-2) that has been studied in cancer therapy , lower back pain , and inflammation , , , .